Peter Wirth is chairman of FORMA Therapeutics Holdings, a privately-held, clinical stage biopharmaceutical company focused on cancer and monogenic diseases; chairman of Syros Pharmaceuticals (Nasdaq: SYRS), clinical stage biopharmaceutical company also focused on cancer and monogenic diseases; and a director of Zai Lab Limited (Nasdaq: ZLAB), a biopharmaceutical company focused on the development and commercialization of innovative products in Greater China. From 2011 to 2014, Mr. Wirth served as co-founder, president and director of Lysosomal Therapeutics, a privately-held biopharmaceutical company focused on research in neurodegenerative diseases. From 1996 to 2011, Mr. Wirth served as a senior executive at Genzyme (Nasdaq: GENZ), which was acquired by Sanofi (Nasdaq: SNY) in 2011, most recently as its executive vice president of legal and corporate development, chief risk officer and corporate secretary. During the last five years, Mr. Wirth also served as a director of Synageva BioPharma Corp. (Nasdaq: GEVA), a biopharmaceutical company which was acquired by Alexion Pharmaceuticals (Nasdaq: ALXN) in 2015. Mr. Wirth graduated from the University of Wisconsin – Madison and received his law degree from Harvard Law School.
Mr. Wirth currently serves on the Board of Centrexion Therapeutics.